Ashley M. Whitaker, PhD, ABPP-CN
Dr. Ashley Whitaker joined the Cancer and Blood Disease Institute at CHLA after completing an APA-accredited pediatric neuropsychology track internship at the Barrow Neurological Institute at Phoenix Children's Hospital and a two-year APPCN-accredited postdoctoral fellowship in pediatric neuropsychology at The Children's Hospital of Philadelphia. She is board certified in clinical neuropsychology with a subspecialty in pediatric neuropsychology. Dr. Whitaker specializes in neuropsychological evaluation of children and adolescents with conditions related to oncology, inborn errors of metabolism, and leukodystrophies. She is devoted to training and enjoys supervising neuropsychology trainees and medical students with regard to brain-behavior relationships.
Dr. Whitaker's research is focused on neuropsychological sequelae of rare metabolic disorders, oncologic conditions, and pediatric epilepsy, as well as implications of bilingualism on neuropsychological functioning in medically compromised populations.
Neuropsychological functioning related to pediatric oncology (e.g., late-effects of chemotherapy, immunotherapy, and radiation in children with brain tumor and blood cancer), bone marrow transplantation/CAR T cell therapy (for children with oncology, hematology, immunodeficiency, and metabolic conditions), and leukodystrophies.
Education
Alliant International University, Los Angeles: Clinical Psychology
Phoenix Children's Hospital/Barrow Neurological Institute: Pediatric Neuropsychology
The Children's Hospital of Philadelphia/University of Pennsylvania Biomedical Postdoctoral Program: Pediatric Neuropsychology
Accomplishments
Board Certified in Clinical Neuropsychology
Board Certified Subspecialist in Pediatric Neuropsychology
American Board of Clinical Neuropsychology (ABCN)
International Neuropsychological Society (INS)
American Academy of Clinical Neuropsychology (AACN)
American Psychological Association (APA)
Division 40: Clinical Neuropsychology
Publications
Research
Long-term neuropsychological sequelae of various medical conditions and treatment protocols, as well as the role of bilingualism in medically fragile populations